查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球癌症生物标记市场评估：按类型、技术、癌症类型、应用、最终用户、地区、机会、预测（2017-2031）
市场调查报告书
商品编码
1417604

全球癌症生物标记市场评估：按类型、技术、癌症类型、应用、最终用户、地区、机会、预测（2017-2031）

Cancer Biomarkers Market Assessment, By Type, By Technology, By Cancer Type, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 224 Pages | 商品交期: 3-5个工作天内

价格

全球癌症生物标记市场规模预计到2023年将达到151亿美元，2031年将达到435.3亿美元，2024-2031年预测期间复合年增长率为14.15%。由于癌症生物标记研究环境的发展，全球癌症生物标记市场预计将成长。癌症生物标记是一种高效的癌症检测方法，因为它们可以提供精确的诊断，而各个市场公司正在进行研究以寻找更有效和更准确的癌症生物标记。

近年来，由于基因突变、生活方式改变、吸烟和饮酒等因素，癌症患者数量显着增加。越来越多的癌症患者需要更准确、更快速的筛检方法，推动市场成长。癌症患者盛行率的增加和尖端技术预计将推动市场成长。癌症患者数量的增加、政府措施、监管政策和技术进步等因素预计将推动市场成长。

2023 年 7 月，领先的诊断资讯服务供应商 Quest Diagnostics 宣布透过病理亚专业公司 AmeriPath 与 Envision Sciences 合作推出一种新型前列腺癌生物标记测试。这项新的基于组织的检测服务旨在满足临床对识别和区分男性前列腺癌潜在侵袭性病例的迫切临床需求。此类尖端产品的批准预计将在推动全球癌症生物标记市场方面发挥关键作用。

增加癌症生物标记的研究和开发

无论是在已开发国家或发展中国家，癌症都是全球主要死亡原因之一。癌症生物标记极大地有助于癌症筛检。在政府当局、投资者和监管机构的支持下，研究机构和市场参与者持续致力于癌症生物标记研究。研究主要集中在识别、优化和利用各种生物标记来推进癌症诊断、研究和治疗。因此，政府和癌症生物标记领域的公司增加研发投资预计将推动市场成长。

2023 年 4 月，佛罗里达州立大学化学家领导的团队开发了一种新测试，可检测与多种癌症相关的生物标记。此检测平台由金奈米颗粒和用染料标记的胜□分子製成。金奈米颗粒可防止染料在紫外线下发光。当将含有酵素 MMP-14（一种癌症生物标记）的患者样本添加到样本製备中时，□键被裂解，染色片段与金分离。如果没有金来吸收染料的能量，样本就会开始发光，从而检测到癌症的存在。

越来越多地关注蛋白质生物标誌物

蛋白质生物标记不仅吸引了患者的关注，也吸引了癌症筛检医学专业人士的注意。如果蛋白质生物标记在癌症患者中持续表达，那么其作为癌症预测因子的可靠性就非常重要。此外，如果蛋白质生物标记广泛表达，则更容易将其识别为生物标记。基于定量分析的蛋白质体学工具已被用来识别癌症生物标记。人们对用于癌症筛检的蛋白质生物标记的日益关注预计将增加基于蛋白质生物标记的癌症筛检的市场需求。

2023 年 6 月，丹麦生物标记公司 Nordic Bioscience 宣布其 PRO-C3 生物标记检测获得 FDA 的支持函 (LoS)。PRO C3 是世界上第一个基于蛋白质生物标记的血液肿瘤纤维化生物标记物，适用于晚期实体瘤患者。全球癌症生物标记市场上有前途的产品的监管批准预计将有助于未来几年的市场成长。

本报告研究分析了全球癌症生物标记市场，提供市场规模和预测、市场动态、主要参与者现状和前景等。

目录

第一章研究方法论

第二章 专案范围与定义

第三章 COVID-19对全球癌症生物标记市场的影响

第 4 章执行摘要

第五章全球癌症生物标记市场展望（2017-2031）

  • 市场规模及预测
    • 金钱数额
    • 数量
  • 按类型
    • 蛋白质生物标记
    • 基因生物标记
    • 其他癌症生物标记
  • 按技术
    • 组学
    • 影像技术
    • 免疫测定
    • 生物信息学
    • 细胞遗传学
  • 按癌症类型
    • 乳腺癌
    • 肺癌
    • 大肠癌
    • 黑色素瘤
    • 血癌
    • 前列腺癌
    • 卵巢癌
    • 胃癌
    • 肝癌
    • 其他癌症
  • 按用途
    • 诊断
    • 研究与开发
    • 预后
    • 风险评估
    • 治疗
    • 其他用途
  • 按最终用户
    • 製药公司、生技公司
    • 诊断实验室
    • 癌症研究所
    • 其他
  • 按地区
    • 北美
    • 欧洲
    • 亚太地区
    • 南美洲
    • 中东/非洲
  • 市场占有率：依公司划分（2023 年）

第六章 全球癌症生物标记市场展望（2017-2031）

  • 北美
    • 市场规模及预测
    • 按类型
    • 按技术
    • 按癌症类型
    • 按用途
    • 按最终用户
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 英国
    • 俄罗斯
    • 荷兰
    • 西班牙
    • 土耳其
    • 波兰
  • 南美洲
    • 巴西
    • 阿根廷
  • 亚太地区
    • 印度
    • 中国
    • 日本
    • 澳大利亚
    • 越南
    • 韩国
    • 印度尼西亚
    • 菲律宾
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯联合酋长国
    • 南非

第 7 章 市场测绘（2023）

  • 按类型
  • 按技术
  • 按癌症类型
  • 按用途
  • 按最终用户
  • 按地区

第八章 宏观环境与产业结构

  • 供需分析
  • 进出口分析 - 数量和价值
  • 供应/价值链分析
  • PESTEL 分析
  • 波特五力分析

第九章市场动态

  • 增长动力
  • 成长限制因素（问题、限制因素）

第十章 监理框架与创新

  • 临床试验
  • 专利情况
  • 监管审批
  • 创新/新技术

第十一章 主要公司情况

  • 前 5 名市场领导者的竞争矩阵
  • 前 5 名市场领导者的市场收入分析（2023 年）
  • 併购/合资（如适用）
  • SWOT分析（5家进入市场的公司）
  • 专利分析（如果适用）

第12章价格分析

第十三章案例研究

第十四章 主要公司展望

  • Abbott
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • QIAGEN
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies, Inc.
  • Quest Diagnostics Incorporated
  • Merck KGaA
  • Hologic, Inc.
  • Bio-Rad Laboratories

第十五章 战略建议

第十六章 关于我们公司、免责声明

Product Code: MX10898

Global cancer biomarkers market size was valued at USD 15.1 billion in 2023, which is expected to reach USD 43.53 billion in 2031, with a CAGR of 14.15% for the forecast period between 2024 and 2031F. The global cancer biomarkers market is expected to grow due to the growing research environment around cancer biomarkers. Cancer biomarkers are a highly effective way of cancer detection as they offer precision diagnostics, since various market players are researching to find more effective and precise cancer biomarkers.

The number of cancer cases has significantly increased in recent years due to factors like genetic mutations, changing lifestyles, smoking, and alcohol consumption. Increasing cancer cases demand more precise and rapid screening methods, which foster market growth. The growing prevalence of cancer patients coupled with cutting-edge technologies is expected to fuel market growth. Factors such as the increasing prevalence of cancer patients, government initiatives, regulatory policies, and technological advancements are expected to fuel market growth.

In July 2023, Quest Diagnostics, the leading provider of diagnostic information services, announced the launch of a novel prostate cancer biomarker test through its subspecialty pathology business, AmeriPath, in collaboration with Envision Sciences. The new, tissue-based test service is intended to address the pressing clinical need for tests to help identify and differentiate potentially aggressive cases of prostate cancer in men. Such cutting-edge product approvals are expected to play a significant role in driving the global cancer biomarkers market.

Increasing Research and Development in Cancer Biomarkers

Cancer is one of the leading causes of death globally, without any exception in developed or developing countries. Cancer biomarkers have been significant contributors to cancer screening. Research institutes and market players are consistently involved in cancer biomarker research which is being supported by government authorities, investors, and regulatory bodies. Research is mainly focused on the identification, optimization, and utilization of different biomarkers to facilitate cancer diagnosis, research, and treatment. Thus, increasing investment by the government in research and development along with companies working in cancer biomarkers space are expected to fuel market growth.

In April 2023, a team led by Florida State University chemists developed a new test for detecting biological markers related to several types of cancer. The sensing platform is made of a gold nanoparticle and molecules called peptides that are labeled with a dye. Chemical bonds connect the components, while the gold nanoparticle restrains the dye from glowing in the presence of UV light. When a patient sample containing Enzyme MMP-14 (a cancer biomarker) is added to the preparation, the peptide bond is broken, separating a fragment with the dye from the gold. Without the gold to absorb the energy from the dye, the sample begins to glow, thus detecting the cancer presence.

Increasing Focus on Protein Biomarker

Protein biomarkers are gaining attention from healthcare professionals as well as patients for cancer screening. The reliability of the protein biomarker as a cancer predictor is of great significance if it is consistently expressed in cancer patients. Furthermore, the protein biomarker's widespread expression can facilitate its identification as a biomarker. Mass spectroscopy-based proteomics tools are utilized for the identification of cancer biomarkers. The increasing focus on protein biomarkers for cancer screening is expected to increase the market demand for protein biomarker-based cancer screenings.

In June 2023, Danish biomarker company Nordic Bioscience announced that its PRO-C3 biomarker assay had received a Letter of Support (LoS) from the United States Food and Drug Administration. PRO C3 is the world's first blood-based tumor fibrosis biomarker based on protein biomarkers for patients with aggressive solid tumors. Regulatory approval of promising products in the global cancer biomarkers market is anticipated to contribute to market growth in forecast years.

Government Initiatives

Government initiatives such as providing research funding, drafting supportive policies, and promoting investments for new establishments are some of the major driving forces for the market. In the global cancer biomarkers market, government organizations, associations, and agencies actively promote cancer screening and treatments through awareness initiatives, thereby fostering the market growth. The governments of several countries are funding research projects addressing cancer diagnostic techniques.

According to a press release from The White House, in March 2023, the United States government invested USD 394.5 million in three CDC programs, National Comprehensive Cancer Control Program, National Breast and Cervical Cancer Early Detection Programs, and Colorectal Cancer Control Program to address the need of screening and treatment of most prevalent type of cancer. In June 2023, as part of the Cancer Moonshot Research Initiatives, the National Institutes of Health, the FNIH, and twelve top pharmaceutical companies announced the start of the five-year, USD 220 million Partnership for Accelerating Cancer Therapies (PACT). PACT is concentrated on finding, creating, and validating strong biomarkers to promote novel treatments and therapies that engage the immune system to combat cancer. The FDA has an advising role in the partnership, which the FNIH manages.

Impact of COVID-19

COVID-19 had a notable impact on the global cancer biomarkers market. During the pandemic COVID-19 patients were of highest priority for healthcare professionals and highlighted the significance of cancer diagnostics and early detection. Cancer biomarkers, which play a pivotal role in the identification of cancer and the monitoring of treatment responses, gained increased attention as healthcare systems worldwide recognized the importance of bolstering cancer care infrastructure. Despite some disruptions in routine cancer screening programs, the pandemic accelerated the adoption of telemedicine and remote monitoring, highlighting the potential for using biomarkers in novel ways. Moreover, the urgent need for more accurate and efficient diagnostic tools spurred research and development efforts in the field of cancer biomarkers. As healthcare systems and hospitals recovered from the pandemic's disruptions, the global cancer biomarkers market saw strong growth, with an increased emphasis on early cancer detection and personalized treatment.

Key Players Landscape and Outlook

Market players are employing a range of strategies to increase their product offerings and give customers access to a wide selection of innovative products. Additionally, companies are expanding the range of diagnostic services offered to capture a bigger portion of the market. Many major industry players are using various growth techniques, like partnerships, mergers and acquisitions, development and launch of new goods, to strengthen their position in the worldwide market.

In September 2023, Ibex launched Galen Breast HER2, an AI-powered solution that helps pathologists for accurate and reproducible biomarker scoring in breast cancer patients. Ibex's Galen Breast HER2 is an AI-powered HER2 receptor scoring system that detects and quantifies the HER2 expression in breast cancer cases and scores it based on 2018 ASCO/CAP scoring guidelines. It can be utilized in screening and checking the effectiveness of treatment being provided to breast cancer patients.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on Global Cancer Biomarkers Market

4. Executive Summary

5. Global Cancer Biomarkers Market Outlook, 2017-2031F

  • 5.1 Market Size & Forecast
    • 5.1.1 By Value
    • 5.1.2 By Volume
  • 5.2 By Type
    • 5.2.1 Protein Biomarkers
    • 5.2.2 Genetic Biomarkers
      • 5.2.2.1 Breast Cancer Genetic Biomarkers
      • 5.2.2.2 Colorectal Cancer Genetic Biomarkers
      • 5.2.2.3 Leukemia Genetic Biomarkers
      • 5.2.2.4 Lung Cancer Genetic Biomarkers
      • 5.2.2.5 Prostate Cancer Genetic Biomarkers
      • 5.2.2.6 Other Cancer Genetic Biomarkers
    • 5.2.3 Other Cancer Biomarkers
  • 5.3 By Technology
    • 5.3.1 OMICS
      • 5.3.1.1 Proteomics
      • 5.3.1.2 Genomics
      • 5.3.1.2.1 Next Generation Sequencing (NGS)
      • 5.3.1.2.2 Polymerase Chain Reaction (PCR)
      • 5.3.1.2.3 Others
      • 5.3.1.3 Other OMICS Technology
    • 5.3.2 Imaging Technology
      • 5.3.2.1 Magnetic Resonance Imaging (MRI)
      • 5.3.2.2 Computed Tomography (CT)
      • 5.3.2.3 Positron Emission Tomography (PET)
      • 5.3.2.4 Mammography
      • 5.3.2.5 Ultrasound
    • 5.3.3 Immunoassays
    • 5.3.4 Bioinformatics
    • 5.3.5 Cytogenetics
      • 5.3.5.1 In-situ Hybridization (ISH)
      • 5.3.5.2 Other Cytogenetics Based Tests
  • 5.4 By Cancer Type
    • 5.4.1 Breast Cancer
    • 5.4.2 Lung Cancer
    • 5.4.3 Colorectal Cancer
    • 5.4.4 Melanoma
    • 5.4.5 Blood Cancer
    • 5.4.6 Prostate Cancer
    • 5.4.7 Ovarian Cancer
    • 5.4.8 Stomach Cancer
    • 5.4.9 Liver Cancer
    • 5.4.10 Other Cancer
  • 5.5 By Application
    • 5.5.1 Diagnostics
    • 5.5.2 Research and Development
    • 5.5.3 Prognostics
    • 5.5.4 Risk Assessment
    • 5.5.5 Treatment
    • 5.5.6 Other Applications
  • 5.6 By End-user
    • 5.6.1 Pharmaceutical and Biotechnological Companies
    • 5.6.2 Diagnostic Laboratories
    • 5.6.3 Cancer Research Institutes
    • 5.6.4 Others
  • 5.7 By Region
    • 5.7.1 North America
    • 5.7.2 Europe
    • 5.7.3 Asia Pacific
    • 5.7.4 South America
    • 5.7.5 Middle East & Africa
  • 5.8 By Company Market Share (%), 2023

6. Global Cancer Biomarkers Market Outlook, 2017-2031F

  • 6.1. North America*
    • 6.1.1. Market Size & Forecast
      • 6.1.1.1. By Value
      • 6.1.1.2. By Volume
    • 6.1.2. By Type
      • 6.1.2.1. Protein Biomarkers
      • 6.1.2.2. Genetic Biomarkers
      • 6.1.2.2.1. Breast Cancer Genetic Biomarkers
      • 6.1.2.2.2. Colorectal Cancer Genetic Biomarkers
      • 6.1.2.2.3. Leukemia Genetic Biomarkers
      • 6.1.2.2.4. Lung Cancer Genetic Biomarkers
      • 6.1.2.2.5. Prostate Cancer Genetic Biomarkers
      • 6.1.2.2.6. Other Cancer Genetic Biomarkers
      • 6.1.2.3. Other Cancer Biomarkers
    • 6.1.3. By Technology
      • 6.1.3.1. OMICS
      • 6.1.3.1.1. Proteomics
      • 6.1.3.1.2. Genomics
      • 6.1.3.1.2.1. Next Generation Sequencing (NGS)
      • 6.1.3.1.2.2. Polymerase Chain Reaction (PCR)
      • 6.1.3.1.2.3. Others
      • 6.1.3.1.3. Other OMICS Technology
      • 6.1.3.2. Imaging Technology
      • 6.1.3.2.1. Magnetic Resonance Imaging (MRI)
      • 6.1.3.2.2. Computed Tomography (CT)
      • 6.1.3.2.3. Positron Emission Tomography (PET)
      • 6.1.3.2.4. Mammography
      • 6.1.3.2.5. Ultrasound
      • 6.1.3.3. Immunoassays
      • 6.1.3.4. Bioinformatics
      • 6.1.3.5. Cytogenetics
      • 6.1.3.5.1. In-situ Hybridization (ISH)
      • 6.1.3.5.2. Other Cytogenetics Based Tests
    • 6.1.4. By Cancer Type
      • 6.1.4.1. Breast Cancer
      • 6.1.4.2. Lung Cancer
      • 6.1.4.3. Colorectal Cancer
      • 6.1.4.4. Melanoma
      • 6.1.4.5. Blood Cancer
      • 6.1.4.6. Prostate Cancer
      • 6.1.4.7. Ovarian Cancer
      • 6.1.4.8. Stomach Cancer
      • 6.1.4.9. Liver Cancer
      • 6.1.4.10. Other Cancer
    • 6.1.5. By Application
      • 6.1.5.1. Diagnostics
      • 6.1.5.2. Research and Development
      • 6.1.5.3. Prognostics
      • 6.1.5.4. Risk Assessment
      • 6.1.5.5. Treatment
      • 6.1.5.6. Other Applications
    • 6.1.6. By End-user
      • 6.1.6.1. Hospitals
      • 6.1.6.2. Pharmaceutical and Biotechnological Companies
      • 6.1.6.3. Diagnostic Laboratories
      • 6.1.6.4. Cancer Research Institutes
      • 6.1.6.5. Others
    • 6.1.7. United States*
      • 6.1.7.1. Market Size & Forecast
      • 6.1.7.1.1. By Value
      • 6.1.7.1.2. By Volume
      • 6.1.7.2. By Type
      • 6.1.7.2.1. Protein Biomarkers
      • 6.1.7.2.2. Genetic Biomarkers
      • 6.1.7.2.2.1. Breast Cancer Genetic Biomarkers
      • 6.1.7.2.2.2. Colorectal Cancer Genetic Biomarkers
      • 6.1.7.2.2.3. Leukemia Genetic Biomarkers
      • 6.1.7.2.2.4. Lung Cancer Genetic Biomarkers
      • 6.1.7.2.2.5. Prostate Cancer Genetic Biomarkers
      • 6.1.7.2.2.6. Other Cancer Genetic Biomarkers
      • 6.1.7.2.3. Other Cancer Biomarkers
      • 6.1.7.3. By Technology
      • 6.1.7.3.1. OMICS
      • 6.1.7.3.1.1. Proteomics
      • 6.1.7.3.1.2. Genomics
      • 6.1.7.3.1.2.1. Next Generation Sequencing (NGS)
      • 6.1.7.3.1.2.2. Polymerase Chain Reaction (PCR)
      • 6.1.7.3.1.2.3. Others
      • 6.1.7.3.1.3. Other OMICS Technology
      • 6.1.7.3.2. Imaging Technology
      • 6.1.7.3.2.1. Magnetic Resonance Imaging (MRI)
      • 6.1.7.3.2.2. Computed Tomography (CT)
      • 6.1.7.3.2.3. Positron Emission Tomography (PET)
      • 6.1.7.3.2.4. Mammography
      • 6.1.7.3.2.5. Ultrasound
      • 6.1.7.3.3. Immunoassays
      • 6.1.7.3.4. Bioinformatics
      • 6.1.7.3.5. Cytogenetics
      • 6.1.7.3.5.1. In-situ Hybridization (ISH)
      • 6.1.7.3.5.2. Other Cytogenetics Based Tests
      • 6.1.7.4. By Cancer Type
      • 6.1.7.4.1. Breast Cancer
      • 6.1.7.4.2. Lung Cancer
      • 6.1.7.4.3. Colorectal Cancer
      • 6.1.7.4.4. Melanoma
      • 6.1.7.4.5. Blood Cancer
      • 6.1.7.4.6. Prostate Cancer
      • 6.1.7.4.7. Ovarian Cancer
      • 6.1.7.4.8. Stomach Cancer
      • 6.1.7.4.9. Liver Cancer
      • 6.1.7.4.10. Other Cancer
      • 6.1.7.5. By Application
      • 6.1.7.5.1. Diagnostics
      • 6.1.7.5.2. Research and Development
      • 6.1.7.5.3. Prognostics
      • 6.1.7.5.4. Risk Assessment
      • 6.1.7.5.5. Treatment
      • 6.1.7.5.6. Other Applications
      • 6.1.7.6. By End-user
      • 6.1.7.7. Hospitals
      • 6.1.7.8. Pharmaceutical and Biotechnological Companies
      • 6.1.7.9. Diagnostic Laboratories
      • 6.1.7.10. Cancer Research Institutes
      • 6.1.7.11. Others
    • 6.1.8. Canada
    • 6.1.9. Mexico

All segments will be provided for all regions and countries covered:

  • 6.2. Europe
    • 6.2.1. Germany
    • 6.2.2. France
    • 6.2.3. Italy
    • 6.2.4. United Kingdom
    • 6.2.5. Russia
    • 6.2.6. Netherlands
    • 6.2.7. Spain
    • 6.2.8. Turkey
    • 6.2.9. Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
  • 6.4. Asia-Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2023

  • 7.1. By Type
  • 7.2. By Technology
  • 7.3. By Cancer Type
  • 7.4. By Application
  • 7.5. By End-user
  • 7.6. By Region

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis - Volume and Value
  • 8.3. Supply/Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

  • 10.1. Clinical Trials
  • 10.2. Patent Landscape
  • 10.3. Regulatory Approvals
  • 10.4. Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. Abbott
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. Thermo Fisher Scientific Inc.
  • 14.3. Illumina, Inc.
  • 14.4. QIAGEN
  • 14.5. F. Hoffmann-La Roche Ltd
  • 14.6. Agilent Technologies, Inc.
  • 14.7. Quest Diagnostics Incorporated
  • 14.8. Merck KGaA
  • 14.9. Hologic, Inc.
  • 14.10. Bio-Rad Laboratories

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 3. Global Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 4. Global Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 5. Global Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 6. Global Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 7. Global Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 8. Global Cancer Biomarkers Market Share (%), By Region, 2017-2031F
  • Figure 9. North America Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 10. North America Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 11. North America Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 12. North America Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 13. North America Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 14. North America Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 15. North America Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 16. North America Cancer Biomarkers Market Share (%), By Country, 2017-2031F
  • Figure 17. United States Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 18. United States Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 19. United States Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 20. United States Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 21. United States Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 22. United States Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 23. United States Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 24. Canada Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 25. Canada Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 26. Canada Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 27. Canada Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 28. Canada Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 29. Canada Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 30. Canada Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 31. Mexico Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 32. Mexico Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 33. Mexico Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 34. Mexico Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 35. Mexico Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 36. Mexico Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 37. Mexico Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 38. Europe Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 39. Europe Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 40. Europe Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 41. Europe Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 42. Europe Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 43. Europe Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 44. Europe Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 45. Europe Cancer Biomarkers Market Share (%), By Country, 2017-2031F
  • Figure 46. Germany Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. Germany Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 48. Germany Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 49. Germany Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 50. Germany Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 51. Germany Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 52. Germany Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 53. France Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 54. France Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 55. France Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 56. France Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 57. France Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 58. France Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 59. France Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 60. Italy Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 61. Italy Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 62. Italy Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 63. Italy Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 64. Italy Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 65. Italy Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 66. Italy Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 67. United Kingdom Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 68. United Kingdom Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 69. United Kingdom Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 70. United Kingdom Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 71. United Kingdom Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 72. United Kingdom Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 73. United Kingdom Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 74. Russia Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 75. Russia Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 76. Russia Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 77. Russia Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 78. Russia Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 79. Russia Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 80. Russia Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 81. Netherlands Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 82. Netherlands Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 83. Netherlands Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 84. Netherlands Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 85. Netherlands Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 86. Netherlands Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 87. Netherlands Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 88. Spain Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Spain Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 90. Spain Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 91. Spain Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 92. Spain Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 93. Spain Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 94. Spain Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 95. Turkey Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 96. Turkey Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 97. Turkey Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 98. Turkey Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 99. Turkey Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 100. Turkey Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 101. Turkey Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 102. Poland Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 103. Poland Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 104. Poland Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 105. Poland Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 106. Poland Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 107. Poland Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 108. Poland Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 109. South America Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 110. South America Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 111. South America Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 112. South America Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 113. South America Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 114. South America Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 115. South America Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 116. South America Cancer Biomarkers Market Share (%), By Country, 2017-2031F
  • Figure 117. Brazil Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 118. Brazil Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 119. Brazil Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 120. Brazil Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 121. Brazil Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 122. Brazil Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 123. Brazil Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 124. Argentina Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 125. Argentina Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 126. Argentina Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 127. Argentina Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 128. Argentina Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 129. Argentina Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 130. Argentina Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 131. Asia-Pacific Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 132. Asia-Pacific Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 133. Asia-Pacific Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 134. Asia-Pacific Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 135. Asia-Pacific Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 136. Asia-Pacific Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 137. Asia- Pacific Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 138. Asia-Pacific Cancer Biomarkers Market Share (%), By Country, 2017-2031F
  • Figure 139. India Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 140. India Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 141. India Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 142. India Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 143. India Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 144. India Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 145. India Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 146. China Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 147. China Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 148. China Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 149. China Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 150. China Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 151. China Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 152. China Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 153. Japan Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 154. Japan Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 155. Japan Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 156. Japan Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 157. Japan Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 158. Japan Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 159. Japan Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 160. Australia Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 161. Australia Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 162. Australia Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 163. Australia Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 164. Australia Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 165. Australia Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 166. Australia Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 167. Vietnam Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 168. Vietnam Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 169. Vietnam Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 170. Vietnam Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 171. Vietnam Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 172. Vietnam Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 173. Vietnam Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 174. South Korea Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 175. South Korea Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 176. South Korea Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 177. South Korea Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 178. South Korea Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 179. South Korea Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 180. South Korea Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 181. Indonesia Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. Indonesia Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 183. Indonesia Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 184. Indonesia Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 185. Indonesia Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 186. Indonesia Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 187. Indonesia Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 188. Philippines Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 189. Philippines Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 190. Philippines Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 191. Philippines Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 192. Philippines Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 193. Philippines Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 194. Philippines Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 195. Middle East & Africa Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 196. Middle East & Africa Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 197. Middle East & Africa Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 198. Middle East & Africa Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 199. Middle East & Africa Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 200. Middle East & Africa Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 201. Middle East & Africa Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 202. Middle East & Africa Cancer Biomarkers Market Share (%), By Country, 2017-2031F
  • Figure 203. Saudi Arabia Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 204. Saudi Arabia Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 205. Saudi Arabia Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 206. Saudi Arabia Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 207. Saudi Arabia Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 208. Saudi Arabia Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 209. Saudi Arabia Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 210. UAE Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 211. UAE Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 212. UAE Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 213. UAE Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 214. UAE Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 215. UAE Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 216. UAE Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 217. South Africa Cancer Biomarkers Market, By Value, In USD Billion, 2017-2031F
  • Figure 218. South Africa Cancer Biomarkers Market, By Volume, In Thousand Units, 2017-2031F
  • Figure 219. South Africa Cancer Biomarkers Market Share (%), By Type, 2017-2031F
  • Figure 220. South Africa Cancer Biomarkers Market Share (%), By Technology, 2017-2031F
  • Figure 221. South Africa Cancer Biomarkers Market Share (%), By Cancer Type, 2017-2031F
  • Figure 222. South Africa Cancer Biomarkers Market Share (%), By Application, 2017-2031F
  • Figure 223. South Africa Cancer Biomarkers Market Share (%), By End-user, 2017-2031F
  • Figure 224. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 225. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 226. By Cancer Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 227. By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 228. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 229. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023